We focus on mechanisms of relapse after CAR-T therapy. Our goal is to design innovative combined IMT for relapsing/refractory Leukemia & Lymphoma. @MarcoRuella
Philadelphia, PA
Joined December 2019
- Tweets57
- Following50
- Followers268
- Likes49
Pinned Tweet
Ruella Lab is proud to announce that @MarcoRuella has won @BloodCancerUtd Greater Philadelphia Visionary of the Year!
Thanks to all supporters to our campaign, YOU made a HUGE contribution to fight cancer!
@PennMedicine
#CellCoast2026 as Marco Ruella, MD (@MarcoRuell), and Adam Cohen, MD, of @PennMedicine discuss immune-related adverse events and BCMA CAR T-cell therapy
Tune in from #CellCoast2026 as Marco Ruella, MD (@MarcoRuella), and Adam Cohen, MD, of @PennMedicine discuss immune-related adverse events and BCMA CAR T-cell therapy.
#CellCoast2026: Marco Ruella, MD (@MarcoRuella), of @PennMedicine, discusses the relationship between antibiotics and CAR T-cell therapy with Roni Shouval, MD, PhD (@RShouval), of @MSKCancerCenter. 🧬🔬
Live from #CellCoast2026: Roni Shouval, MD, PhD (
@RShouval), of @MSKCancerCenter joins Marco Ruella, MD (@MarcoRuella), of @PennMedicine, to discuss the relationship between antibiotics and CART.
#CellCoast2026: Marco Ruella, MD (@MarcoRuella), of @PennMedicine, joins Stephen Bagley, MD, to share advances in intracerebroventricular CAR T-cell therapy for glioblastoma. 🧠🔬
Tune in as Stephen Bagley, MD, and Marco Ruella, MD (@MarcoRuella), of @PennMedicine share advances in intracerebroventricular CAR T-cell therapy for glioblastoma at #CellCoast2026.
#CellCoast2026: Marco Ruella, MD (@MarcoRuella), of @PennMedicine, discusses the future of JAK inhibition and CAR T-cell therapy with Michael Jain, MD, PhD (@MichaelDJain), of @MoffittNews. 🧬🔬
What's next for JAK inhibition and CAR T-cell therapy?
Michael Jain, MD, PhD (@MichaelDJain), of @MoffittNews, joins Marco Ruella, MD (@MarcoRuella), of @PennMedicine, to discuss at #CellCoast2026.
#CellCoast2026: Marco Ruella, MD (@MarcoRuella), of @PennMedicine, shares insights into Penn’s work on IL-18 CAR T-cell therapy. 🧬🔬
Live from #CellCoast2026: Jakub Svoboda, MD, joins Marco Ruella, MD (@MarcoRuella), of @PennMedicine to share insights on Penn’s work with IL-18 CAR T-cell therapy.
Analysis of longitudinal blood samples shows that #CD19 #CARTs can be detected at least 10 years post-treatment in patients with #lymphoma, with deeper profiling from a single patient showing that these CARTs have a dominant double negative activated effector memory-like phenotype.
@MarcoRuella @ruellalab @pennmedicine @paruzzol
nature.com/articles/s41591-0…
We are excited to share our work demonstrating 10-year remissions after one infusion of Tisa-cel in B-NHL patients!
nejm.org/doi/abs/10.105
We thank all the patients & families, as well as the clinical & research teams that made this work possible.
@MarcoRuella @PennMedicine
In last week's episode of Blood Podcast, editor Dr. Laura Michaelis interviews @MarcoRuella on recent work on harnessing the CD2 axis to enhance CAR T-cell therapies.
@PennMedicine
share.transistor.fm/s/ce15a7…
For those of you in Philly, come support our bake sale in the Perelman Center upstairs lobby! 🍪 🍰
All proceeds will support Blood Cancer United! 🩸
Great job to our PhD candidate Audrey for the wonderful presentation at @ISCTglobal! Read more about this work in our @ScienceTM publication.
Also great presentation by Dr. Bruce Levine (@BLLPHD), thank you for featuring our work from @CellCellPress
@MarcoRuella @PennMedicine
Amazing presentation this morning at CCI, @PennCancer @PennMedCSO!
• @MarcoRuella presented correlative data from the Phase 1 Senza5-CAR5 study;
• @LemoineJean6 introduced a novel CAR T-cell design targeting IGHV1-69 on B-cell receptors.
Proud to help develop next-gen CAR T!
Ruella Lab retweeted
Harnessing the CD2 axis to broaden & enhance the efficacy of CAR T-cell therapies ft. @AlbertoCarturan, @Mat_Angelos & @MarcoRuella (@PennCancer) @RuellaLab @BloodPortfolio ashpublications.org/blood/ar…
Congrats to @BernhardDumoul1, @KSusztak, and the rest of the Susztak lab for the amazing work in @Nature! We are happy to be involved, and excited to see what comes next!
@PennMedicine @MarcoRuella
🗞️📸🌟🤩Beautiful work led by @BernhardDumoul1 with the team builds a single cell spatial atlas of human DKD using Xenium + CosMx + snRNA-seq. @Nature This is not incremental. This is a new layer of pathology. Diabetic kidney disease (DKD) is still treated as one disease. That is the problem. Patients look similar clinically but behave very differently. We asked: is there a biologically distinct subgroup we are missing?
rdcu.be/ff6ZZ
A celebration dinner for all of our recent accomplishments!
⭐️ 4 publications out so far in 2026
⭐️ 2 covers (@BloodPortfolio Vol 147 Issue 16, and @ScienceTM Vol 18 Issue 835)
And so much more to come!
@MarcoRuella
Thank you @PennMedicine for the support! And of course thank you @CellCellPress @BloodPortfolio @ScienceTM and @NEJM (out soon) for the opportunity to publish with you all!
Ruella Lab retweeted
CD2 is a viable target for CAR T-cell immunotherapy for T-cell malignancies, but CD2 deletion in CAR T cells can lead to dysfunction. Read in Blood: ow.ly/j41050YKAiI
‼️Ruella Lab at the Heme Malignancies Research in Progress session!
Presenters:
🩸@Shan_Liu_ discusses how host factors such as diet can modulate responses to CAR T-cell therapy
🩸@paruzzol presents on the decade-long persistence of CAR T-cells
@MarcoRuella @PennMedicine
Ruella Lab retweeted
New issue of Blood out now featuring Anti-CD2 CAR T-cells for T-cell neoplasms, Inflammatory landscape in clonal hematopoiesis, GRK5 variant linked to thrombotic disease, and more. Explore here: ashpublications.org/blood/is…
📣Out today in @BloodPortfolio: harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapies.
🔗 authors.elsevier.com/a/1my0Z…
Congrats to @AlbertoCarturan & @Mat_Angelos!
@MarcoRuella @PennMedicine @PennCancer @PennMedCSO
